paclitaxel has been researched along with Acneiform Eruptions in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, E; Birnbaum, A; Dipetrillo, T; Henderson, D; Joyce, D; Kennedy, T; Puthwala, Y; Rathore, R; Ready, N; Safran, H; Sio, TT; Wanebo, H | 1 |
| Bralet, MP; Chebib, A; Gholam, D; Hauteville, D; Jasmin, C | 1 |
1 trial(s) available for paclitaxel and Acneiform Eruptions
| Article | Year |
|---|---|
Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Topics: Acneiform Eruptions; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mucositis; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiodermatitis; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
1 other study(ies) available for paclitaxel and Acneiform Eruptions
| Article | Year |
|---|---|
Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negativ
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cetuximab; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Severity of Illness Index; Skin Neoplasms; Treatment Outcome | 2007 |